Clinical Trials Logo
  1. Home
  2. Altitude Hypoxia
  3. NCT03536429
  4. Details
NCT03536429 Clinical Trial

Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude

Altitude Hypoxia Clinical Trial

Official title:
Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03536429
Other study ID # 2018-01-8/305A
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date May 15, 2018
Est. completion date August 2, 2018

Study information
Verified date October 2021
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized, placebo controlled trial evaluating the effect of acetazolamide on postural control in lowlanders older than 40 years travelling from 760 m to 3'100 m.

Description:

This is a randomized, placebo-controlled, double-blind parallel trial evaluating the effect of preventive acetazolamide intake on the postural control in lowlanders older than 40 years travelling to altitude. Participants living in the Bishkek area, Kyrgyzstan (760m), will be transferred by car within 4h to the Tuja Ashu high altitude clinic (3'100 m), and stay there for 2 days. Acetazolamide 375mg/day (or placebo), will be administered before departure at 760 m and during the stay at altitude. Outcomes will be assessed during the stay at 3'100 m. An interim analysis will be carried out when 80 participants will have completed the study or after the first year. The Peto's method will be used and the trial will be stopped when pre-specified futility boundaries were crossed.

Recruitment information / eligibility
Status Completed
Enrollment 99
Est. completion date August 2, 2018
Est. primary completion date August 2, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - Healthy men and women, age 40-75 yrs, without any disease and need of medication. - Born, raised and currently living at low altitude (<800m). - Written informed consent. - Kyrgyz ethnicity Exclusion Criteria: - Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. - Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol. - Allergy to acetazolamide and other sulfonamides.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• ACETAZOLAMIDE oral capsule
Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
• Placebo oral capsule
Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m

Locations
Country Name City State
Kyrgyzstan National Center of Cardiology and Internal Medicine Bishkek

Sponsors (2)
Lead Sponsor Collaborator
University of Zurich National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

Country where clinical trial is conducted

Kyrgyzstan, 

Outcome
Type Measure Description Time frame Safety issue
Primary Change in anterio-posterior sway velocity (AP) Difference in altitude-induced change (between day 2 at 760 meters a.s.l. vs. day 2 at 3'100 meters a.s.l.) of AP sway velocity between acetazolamide and placebo group, measured by a balance platform Day 2 at 760m and 3'100m
Secondary Change in arterial oxygen saturation Difference in altitude-induced change (between day 2 at 760 meters a.s.l. vs. day 2 at 3'100 meters a.s.l.) of arterial oxygen saturation between acetazolamide and placebo group, measured by pulse oximetry Day 2 at 760m and 3'100m
Secondary Acute mountain sickness, severity Difference in acute mountain sickness severity on day 2 at 3'100 meters a.s.l. between acetazolamide and placebo group. Day 2 at 3'100m
Secondary Change in cerebral tissue oxygenation Difference in altitude-induced change (between day 2 at 760 meters a.s.l. vs. day 2 at 3'100 meters a.s.l.) of cerebral tissue oxygenation between acetazolamide and placebo group, measured by near-infrared spectroscopy. Day 2 at 760m and 3'100m
Secondary Change in muscle tissue oxygenation Difference in altitude-induced change (between day 2 at 760 meters a.s.l. vs. day 2 at 3'100 meters a.s.l.) of muscle tissue oxygenation between acetazolamide and placebo group, measured by near-infrared spectroscopy. Day 2 at 760m and 3'100m
Secondary AP sway velocity with and without study medication Difference in AP sway velocity between acetazolamide and placebo group at 760 m. Day 3 at 760m
See also
  Status Clinical Trial Phase
Completed NCT05603689 - Effect of Isocaloric Ketogenic Diet on Physical Performance at High Altitude N/A
Completed NCT03536455 - Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude Phase 4
Completed NCT03536507 - Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude Phase 4
Completed NCT03536520 - Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude Phase 4
Completed NCT05468515 - Reference Interval for SPO2 in Neonates at High Altitudes During First 2 Hours and Umbilical Artery Blood Gas
Active, not recruiting NCT05966714 - Neonatal Cerebral Oxygenation and Electrical Activity at Different Altitude Levels
Completed NCT04075565 - The Psychophysiological Effect of Simulated and Terrestrial Altitude N/A
Not yet recruiting NCT05867719 - The Physiological Effects of Acute and Ramp Simulated Altitude Exposure During Simulated Flight Tasks N/A
Active, not recruiting NCT04913389 - Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD Phase 3
Active, not recruiting NCT03539367 - Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude Phase 4
Active, not recruiting NCT03540914 - Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude. Phase 4
Active, not recruiting NCT03537924 - Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude Phase 4
Completed NCT03368352 - Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude. Early Phase 1
Enrolling by invitation NCT05971290 - Effects of Continuous Positive Airway Pressure on Peripheral Oxygen Saturation, Work of Breathing, and Exercise Tolerance at Altitude N/A
Completed NCT04751292 - HIGH Altitude CArdiovascular REsearch Latin America Population Study
Completed NCT03707249 - Iron Status and Cardiopulmonary Physiology N/A
Completed NCT03743610 - Physiological Adaptations to Simulated Intermittent Altitude on Human Health and Performance N/A
Active, not recruiting NCT05517044 - The Pre-acclimatization Augmented Extreme Altitude Expedition N/A
Active, not recruiting NCT05500014 - Effect of Altitude on Iron Absorption in Iron Depleted Women N/A